Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is focusing on the development of recombinant proteins and cell immunotherapy, with significant advancements in CAR-T cell therapy and products related to monkeypox virus prevention and treatment [2][3][4]. Group 1: Company Developments - The company has developed high-quality recombinant proteins targeting various diseases, enhancing the biopharmaceutical R&D and production processes [2]. - A specific antibody targeting the CD19 antigen in CAR-T cell therapy has been launched, improving detection methods and expanding the product line related to cell and gene therapy [2]. - The company has initiated product development related to monkeypox, launching several recombinant proteins, antibodies, and test kits to support vaccine and therapeutic drug development [2]. Group 2: Industry Recognition - The company has been recognized as a "specialized and innovative" small giant enterprise, a prestigious title in China, indicating strong innovation capabilities and market leadership [3]. Group 3: Financial Performance - In the 2024 annual report, the company reported that overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. - For the first quarter of 2025, the company achieved a revenue of 186 million yuan, representing a year-on-year growth of 27.73%, and a net profit of 40.58 million yuan, up 32.30% year-on-year [9]. Group 4: Shareholder Information - As of March 31, 2025, the company had 10,600 shareholders, a decrease of 12.07% from the previous period, with an average of 8,548 circulating shares per shareholder, an increase of 13.73% [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [10].
百普赛斯跌0.28%，成交额1.17亿元，近5日主力净流入-2303.38万